1.本数据库收录EMA集中程序以及经HMA协调通过互认可程序或分权程序获得批准上市的药品
2.查询欧盟成员国上市的相关信息，点击欧盟成员国上市
掌握医院、零售、 电商 三大终端市场的销售脉搏，就用 药品市场全终端分析系统 (←点击链接免费试用)
全面洞察药品零售数据，助力企业精准决策，把握市场增长，就用穿云众客-零售药品消费分析决策系统(←点击链接免费试用)
| 商标名 | 通用名称 | 中文名称 | ATC编码 | 授权日期 | 上市许可持有人 | 市场状态 |
|---|---|---|---|---|---|---|
| Durysta | bimatoprost | 贝美前列素 | S01EE03 | AbbVie Deutschland GmbH & Co. KG | Application withdrawn | |
| Cinainu | dry aqueous extract of paullinia cupana seed;dry hydroethanolic extract of theobroma cacao seed;liquid ethanolic extract 30 per cent (W/W) of Allium cepa fresh bulb and Citrus limon fresh fruit | Legacy Healthcare (France) S.A.S. | Opinion under re-examination | |||
| Izelvay | avacincaptad pegol | 培戈-阿伐普他 | S01XA32 | Astellas Pharma Europe B.V. | Application withdrawn | |
| Obodence | denosumab | 地舒单抗 | M05BX04 | 2025-02-12 | Samsung Bioepis NL B.V. | Authorised |
| Xbryk | denosumab | 地舒单抗 | M05BX04 | Samsung Bioepis NL B.V. | Opinion | |
| Lazcluze | lazertinib | L01EB09 | Janssen Cilag International NV | Opinion | ||
| Gohibic | vilobelimab | 韦洛利单抗 | L04AJ10 | 2025-01-13 | InflaRx GmbH | Authorised |
| Ahzantive | aflibercept | 阿柏西普 | S01LA05 | 2025-01-13 | Klinge Biopharma GmbH | Authorised |
| Augtyro | repotrectinib | 瑞普替尼 | L01EX28 | 2025-01-13 | Bristol-Myers Squibb Pharma EEIG | Authorised |
| Kizfizo | temozolomide | 替莫唑胺 | L01AX03 | ORPHELIA Pharma | Opinion | |
| Baiama | aflibercept | 阿柏西普 | S01LA05 | 2025-01-13 | Formycon AG | Authorised |
| Stoboclo | denosumab | 地舒单抗 | M05BX04 | Celltrion Healthcare Hungary Kft. | Opinion | |
| Andembry | garadacimab | 加达西单抗 | B06AC07 | 2025-02-10 | CSL Behring GmbH | Authorised |
| Avtozma | tocilizumab | 托珠单抗 | L04AC07 | Celltrion Healthcare Hungary Kft. | Opinion | |
| Beyonttra | acoramidis | C01EB25 | 2025-02-10 | BridgeBio Europe B.V. | Authorised | |
| Emcitate | tiratricol | 替拉曲考 | H03AA04 | 2025-02-12 | Rare Thyroid Therapeutics International AB | Authorised |
| Eydenzelt | aflibercept | 阿柏西普 | S01LA05 | Celltrion Healthcare Hungary Kft. | Opinion | |
| Kavigale | sipavibart | J06BD09 | 2025-01-20 | AstraZeneca AB | Authorised | |
| Kostaive | zapomeran | J07BX | Arcturus Therapeutics Europe B.V. | Authorised | ||
| Nemluvio | nemolizumab | 奈莫利珠单抗 | D11AH12 | 2025-02-12 | Galderma International | Authorised |
